Dresden, Germany.
London, UK.
Aliment Pharmacol Ther. 2021 Apr;53(7):830-843. doi: 10.1111/apt.16252. Epub 2021 Feb 10.
Cirrhosis develops in <10% of individuals homozygous for the C282Y variant in the homeostatic iron regulator (HFE) gene. Carriage of PCSK7:rs236918 is associated with an increased risk of cirrhosis in this population.
To determine if genetic variants significantly associated with the risk of alcohol- and NAFLD-related cirrhosis also modulate the cirrhosis risk in C282Y homozygotes.
Variants in PCSK7, PNPLA3, TM6SF2, MBOAT7 and HSD17B13 were genotyped in 1319 C282Y homozygotes, from six European countries, of whom 171 (13.0%) had cirrhosis. Genotypic and allelic associations with the risk for developing cirrhosis were assessed, adjusting for age and sex. Fixed effects meta-analyses of the adjusted summary data for each country were performed. Post hoc association testing was undertaken in the 131 (76.6%) cases and 299 (26.0%) controls with available liver histology.
Significant associations were observed between PCSK7:rs236918 (OR = 1.52 [95% CI 1.06-2.19]; P = 0.022; I = 0%); PNPLA3:rs738409 (OR = 1.60 [95% CI 1.22-2.11]; P = 7.37 × 10 ; I = 45.5%) and TM6SF2:rs58542926 (OR = 1.94 [95% CI 1.28-2.95]; P = 1.86 × 10 ; I = 0%) and the cirrhosis risk in C282Y homozygotes. These findings remained significant in the subpopulation with available liver histology. The population-attributable fractions were 5.6% for PCSK7:rs236918, 13.8% for PNPLA3:rs738409, 6.5% for TM6SF2:rs58542926 and 24.0% for carriage of all three variants combined.
The risk of cirrhosis associated with carriage of PCSK7:rs236918 was confirmed in this much larger population of C282Y homozygotes. In addition, PNPLA3:rs738409 and TM6SF2:rs58542926 were established as significant additional risk factors. More detailed genetic testing of C282Y homozygotes would allow risk stratification and help guide future management.
在家稳态铁调节剂(HFE)基因纯合子中,仅有不到 10%的个体发生肝硬化。载脂蛋白 B mRNA 编辑酶催化多肽 7:rs236918 可增加该人群发生肝硬化的风险。
确定与酒精和非酒精性脂肪性肝病相关的肝硬化风险显著相关的遗传变异是否也能调节 C282Y 纯合子的肝硬化风险。
对来自 6 个欧洲国家的 1319 名 C282Y 纯合子个体进行载脂蛋白 B mRNA 编辑酶催化多肽 7、载脂蛋白 C3 基因多态性 317(PNPLA3)、转甲状腺素蛋白(TTR)基因 6 内含子小片段(TM6SF2)、膜结合 O-酰基转移酶 7(MBOAT7)和 17-β-羟类固醇脱氢酶 13(HSD17B13)的基因分型。调整年龄和性别后,评估这些变异与发生肝硬化风险的关系。对每个国家的调整汇总数据进行固定效应荟萃分析。对具有可用肝组织学的 131 例(76.6%)病例和 299 例(26.0%)对照进行事后关联测试。
在 C282Y 纯合子中观察到 PCSK7:rs236918(比值比 [OR] = 1.52 [95% 置信区间 1.06-2.19];P = 0.022;I = 0%)、PNPLA3:rs738409(OR = 1.60 [95% CI 1.22-2.11];P = 7.37×10-4;I = 45.5%)和 TM6SF2:rs58542926(OR = 1.94 [95% CI 1.28-2.95];P = 1.86×10-4;I = 0%)与肝硬化风险显著相关。在具有可用肝组织学的亚组中,这些发现仍然具有统计学意义。人群归因分数分别为 PCSK7:rs236918 为 5.6%、PNPLA3:rs738409 为 13.8%、TM6SF2:rs58542926 为 6.5%,三者共同携带的比例为 24.0%。
在这一更大的 C282Y 纯合子人群中,PCSK7:rs236918 与肝硬化风险的关联得到了证实。此外,PNPLA3:rs738409 和 TM6SF2:rs58542926 也被确定为显著的附加风险因素。对 C282Y 纯合子进行更详细的基因检测,可以进行风险分层,并有助于指导未来的治疗。